Short-Term Outcomes of Elobixibat in Home-Care Patients with Chronic Constipation: A Multicenter, Prospective, Observational Study

The aim of this study was to evaluate short-term outcomes and safety of elobixibat in home-care patients with chronic constipation (CC) and explore the changes in caregiver burden related to bowel management. This multicenter prospective observational study evaluated bowel movement status, defecation-related symptoms, and caregiver burden in home-care patients diagnosed with CC who had hard stools classified as Bristol Stool Form Scale (BSFS) type 1 or 2. Elobixibat was administered to home-care patients once a day for 4 weeks before a meal. The primary endpoint was the proportion of patients with normal stools at week 2 in patients who were able to excrete independently. Secondary endpoints included the proportion of patient with normal stools at week 4, stool consistency, stool frequency, defecation-related symptoms at weeks 2 and 4, caregiver burden at week 4, concomitant laxative use during the study period, and adverse events. Analyses were based on available data at each assessment time point. The proportion of patient with normal stools at week 2 in patients who could excrete independently was 53% (8/15; 95% CI, 30–75%). Weekly defecation frequency significantly increased at week 4 (n = 20, p = 0.02, without multiplicity adjustment) and was associated with potential improvements in defecation-related symptoms (straining, abdominal bloating) and patient satisfaction. The most common adverse event was mild diarrhea (17%), with no new safety signals observed over 4 weeks. The caregiver questionnaire, evaluated in a limited subset of seven respondents, showed preliminary descriptive changes in physical, psychological, and social burdens. This uncontrolled, exploratory observational study suggests that elobixibat was associated with improvements in defecation-related outcomes in home-care patients with CC. However, these findings should be interpreted with caution due to the small sample size and potential confounding from concomitant laxative use. Caregiver burden findings were descriptive and hypothesis-generating and require confirmation in larger, controlled studies.

Authors

Institutions

Publication Details

Journal
Journal of Gerontology and Geriatrics
Published
2026-07-23
DOI
https://doi.org/10.3390/jgg74030023
Primary Topic
Gastrointestinal motility and disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Short-Term Outcomes of Elobixibat in Home-Care Patients with Chronic Constipation: A Multicenter, Prospective, Observational Study

Takahiro Ito, Tsuyoshi Enokihara, Yosuke Tsukinaga, Yasuyuki Kanno et al.
Journal of Gerontology and Geriatrics
Gastrointestinal motility and disorders
article

Short-Term Outcomes of Elobixibat in Home-Care Patients with Chronic Constipation: A Multicenter, Prospective, Observational Study

Takahiro Ito, Tsuyoshi Enokihara, Yosuke Tsukinaga, Yasuyuki Kanno, Kiyoko Tanigawa, Takahiro Yamamoto, Keiko Handa
article en

Abstract

The aim of this study was to evaluate short-term outcomes and safety of elobixibat in home-care patients with chronic constipation (CC) and explore the changes in caregiver burden related to bowel management. This multicenter prospective observational study evaluated bowel movement status, defecation-related symptoms, and caregiver burden in home-care patients diagnosed with CC who had hard stools classified as Bristol Stool Form Scale (BSFS) type 1 or 2. Elobixibat was administered to home-care patients once a day for 4 weeks before a meal. The primary endpoint was the proportion of patients with normal stools at week 2 in patients who were able to excrete independently. Secondary endpoints included the proportion of patient with normal stools at week 4, stool consistency, stool frequency, defecation-related symptoms at weeks 2 and 4, caregiver burden at week 4, concomitant laxative use during the study period, and adverse events. Analyses were based on available data at each assessment time point. The proportion of patient with normal stools at week 2 in patients who could excrete independently was 53% (8/15; 95% CI, 30–75%). Weekly defecation frequency significantly increased at week 4 (n = 20, p = 0.02, without multiplicity adjustment) and was associated with potential improvements in defecation-related symptoms (straining, abdominal bloating) and patient satisfaction. The most common adverse event was mild diarrhea (17%), with no new safety signals observed over 4 weeks. The caregiver questionnaire, evaluated in a limited subset of seven respondents, showed preliminary descriptive changes in physical, psychological, and social burdens. This uncontrolled, exploratory observational study suggests that elobixibat was associated with improvements in defecation-related outcomes in home-care patients with CC. However, these findings should be interpreted with caution due to the small sample size and potential confounding from concomitant laxative use. Caregiver burden findings were descriptive and hypothesis-generating and require confirmation in larger, controlled studies.

Journal of Gerontology and GeriatricsVol. 74(3)
Canon (Japan) (JP), Nakanishi (Japan) (JP), Tochigi Medical Center (JP), Dokkyo Medical University (JP)
EA Pharma Co., Ltd.
Openalex Percentile: Top 8%
Gastrointestinal motility and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.